Pharma Focus Europe

Long Grove Pharmaceuticals Secures Commercial Rights to an Essential Critical Care Medication

Friday, May 05, 2023

Long Grove Pharmaceuticals announced the strategic in-licensing of Norepinephrine in 0.9% Sodium Chloride premix formulation from Nevakar Injectables, Inc. This manufactured, ready-to-use formulation is room-temperature stable and will be available in three commonly administered strengths; 4mg/250mL (16mcg/mL), 8mg/250mL (32mcg/mL), and 16mg/250mL (64mcg/mL), helping strengthen what has historically been a fragile critical care supply chain.

Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting. Nevakar Injectables, Inc. received FDA clearance for Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection as a 505(b)(2) NDA in October 2022.

"Our partnership with Nevakar is aimed at helping increase the reliability related to this essential critical care product.", said Peter Karas, Chief Commercial Officer of Long Grove Pharmaceuticals. "Norepinephrine Premix has the potential to enhance patient safety as well as our customers' operational efficiencies by eliminating the potential risks and complications associated with compounding."

"Nevakar has a long commitment to creating new formulations from existing molecules with the potential to improve the quality of care. Our partnership with Long Grove Pharmaceuticals helps ensure that we have a very experienced commercial team ready to successfully bring this product to market.", said Sriram Ramanathan, Chief Executive Officer of Nevakar Injectables, Inc.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024